Source comparison
IGF-1 LR3 Dosage: Research Protocol Comparison
Conservative Titration 20–40mcg Subcutaneous (abdominal) Non-specific 4–6 weeks Lowest side effect risk; slower hypertrophy rate; suitable for baseline sensitivity assessment Standard Research Range 40–80mcg Intramuscular (target muscle) Post-workout (trained
This comparison does not assign a generated winner or score.
- Conservative Titration
- 20–40mcg
- Subcutaneous (abdominal)
- Non-specific
- 4–6 weeks
- Lowest side effect risk; slower hypertrophy rate; suitable for baseline sensitivity assessment
- Standard Research Range
- 40–80mcg
- Intramuscular (target muscle)
- Post-workout (trained muscle groups)
- Peak anabolic signaling without disproportionate systemic effects; most published data in this range
- High-Dose Protocol
- 80–100mcg
- Intramuscular or subcutaneous
- Post-workout
- 3–4 weeks (shorter due to desensitization)
- Increased side effect incidence (joint pain, hypoglycemia); marginal gains over 40–80mcg range
- Site-Specific Localized
- 30–50mcg per site
- Intramuscular (bilateral target muscles)
- Asymmetric hypertrophy risk if injection sites aren't balanced; requires precise technique
- Every-Other-Day Protocol
- 60–120mcg (1.5× daily dose)
- Subcutaneous or intramuscular
- Post-workout on training days
- 6–8 weeks
- Experimental; may reduce receptor desensitization; less published data
- Professional Assessment
- 40–80mcg daily IM post-workout is the evidence-supported range balancing efficacy, safety, and practical administration. Site-specific IM into trained muscle groups maximizes localized effect.
- Higher doses don't produce proportional gains and increase systemic risks.